ReviewCurrent pain and headache reports2026
Multimodal Management of Pain in Oral Squamous Cell Carcinoma: A Mechanism-Based Approach.
Review in Current pain and headache reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewOral squamous cell carcinoma (OSCC) is frequently associated with severe nociceptive and neuropathic pain that adversely affects patient quality of life, functional capacity, psychological well-being, and prognosis. Pain in OSCC is increasingly recognized not only as a clinical symptom but also as a dynamic indicator of tumor progression and neuroinflammatory activity. This review summarizes the epidemiological, molecular, neurobiological, and clinical mechanisms underlying OSCC-associated pain and discusses current and emerging approaches for mechanism-based multimodal pain management. RECENT
findingsRecent evidence demonstrates that tumor-nerve interactions, perineural invasion, inflammatory cytokines, and peripheral and central sensitization play central roles in the pathogenesis of OSCC pain. Molecular alterations involving TP53 mutations, EGFR overexpression, and PI3K/AKT/mTOR pathway activation contribute to inflammatory signaling, neural remodeling, and nociceptive sensitization within the tumor microenvironment. Advances in salivary biomarkers, liquid biopsy approaches, artificial intelligence-assisted pain assessment, and organoid-based translational models are improving the understanding of cancer pain biology and supporting the development of precision analgesia and individualized therapeutic strategies. OSCC-associated pain is a complex and multidimensional phenomenon closely linked to tumor aggressiveness, neuroinflammation, and disease progression. Effective pain management requires mechanism-based multimodal approaches integrating pharmacological, rehabilitative, interventional, and tumor-directed therapies. Emerging precision medicine strategies, combined with equitable access to supportive care, have the potential to improve pain control, treatment outcomes, patient dignity, and overall quality of life in individuals with OSCC.
Indexed as
Identifiers
42536272What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.